Takahiro Amemiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Takahiro Amemiya has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Hiroshi Suzuki
Department of Pharmacy, Faculty of Medicine, The University of Tokyo Hospital, The University of Tokyo, Tokyo, Japan
3 shared publications- Genki Shinohara
Department of Pharmaceutical Sciences, School of Pharmacy at Narita, International University of Health and Welfare, 845-1 Hatakeda, Narita 286-0124, Chiba, Japan
2 shared publications - Ryosuke Shinkai
Department of Pharmaceutical Sciences, School of Pharmacy at Narita, International University of Health and Welfare, 845-1 Hatakeda, Narita 286-0124, Chiba, Japan
2 shared publications - Takashi Tomita
Department of Pharmaceutical Sciences, School of Pharmacy at Narita, International University of Health and Welfare, 845-1 Hatakeda, Narita 286-0124, Chiba, Japan
2 shared publications - Ayae Nomura
Department of Pharmaceutical Sciences, School of Pharmacy at Narita, International University of Health and Welfare, 845-1 Hatakeda, Narita 286-0124, Chiba, Japan
1 shared publication - Naru Tsukase
Department of Pharmaceutical Sciences, School of Pharmacy at Narita, International University of Health and Welfare, 845-1 Hatakeda, Narita 286-0124, Chiba, Japan
1 shared publication
Latest Publications
- Open Access
- 29 September 2026
- Published by MDPI AG in Environments
- Vol. 13 (10) , 541
Basaltic Geological Context and Regional Variation in Dry-Eye Medication Utilisation in Japan: An Exploratory Ecological Study
Basaltic geological environments represent spatially heterogeneous regional contexts encompassing diverse mineralogical, hydrological, and geochemical characteristics. This nationwide exploratory ecological study examined whether basalt area ratio (BAR) was associated with dry-eye medication prescription volume across the 47 prefectures of Japan. The outcome was the annual number of bottles dispensed per 1000 population for three dry-eye medications in 2022. BAR was calculated using geographic information system data. Associations were evaluated using LOESS, covariate-adjusted restricted cubic splines, univariable and multiple linear regression, and sensitivity analyses using alternative denominators. Neither the overall spline association nor its nonlinear component was statistically significant. BAR was also not significantly associated with medication prescription volume in either the univariable or multiple linear regression analysis. Although the smoothing curves showed descriptive variation across the observed BAR range, the apparent nonlinear pattern was not statistically supported or consistently reproduced across analytical methods. Thus, the available prefecture-level data provided no statistical evidence of an association between basalt coverage and dry-eye medication utilisation. BAR should be interpreted as an indicator of regional geological context rather than as a measure of natural H2 production or human exposure. Future studies should incorporate direct environmental measurements, finer spatial resolution, seasonal data, and clinical dry-eye outcomes.
- 29 September 2026
- Published by MDPI AG in Environments
- Vol. 13 (10) , 541
Open AccessBasaltic Geological Context and Regional Variation in Dry-Eye Medication Utilisation in Japan: An Exploratory Ecological Study
Basaltic geological environments represent spatially heterogeneous regional contexts encompassing diverse mineralogical, hydrological, and geochemical characteristics. This nationwide exploratory ecological study examined whether basalt area ratio (BAR) was associated with dry-eye medication prescription volume across the 47 prefectures of Japan. The outcome was the annual number of bottles dispensed per 1000 population for three dry-eye medications in 2022. BAR was calculated using geographic information system data. Associations were evaluated using LOESS, covariate-adjusted restricted cubic splines, univariable and multiple linear regression, and sensitivity analyses using alternative denominators. Neither the overall spline association nor its nonlinear component was statistically significant. BAR was also not significantly associated with medication prescription volume in either the univariable or multiple linear regression analysis. Although the smoothing curves showed descriptive variation across the observed BAR range, the apparent nonlinear pattern was not statistically supported or consistently reproduced across analytical methods. Thus, the available prefecture-level data provided no statistical evidence of an association between basalt coverage and dry-eye medication utilisation. BAR should be interpreted as an indicator of regional geological context rather than as a measure of natural H2 production or human exposure. Future studies should incorporate direct environmental measurements, finer spatial resolution, seasonal data, and clinical dry-eye outcomes.
- Open Access
- 27 September 2026
- Published by MDPI AG in Environments
- Vol. 13 (10) , 537
Association Between Volcanic Rock Area Ratio and Regional Variation in Acne Medication Utilisation in Japan: A Nationwide Ecological Study
Regional variation in healthcare utilisation is influenced by demographic, healthcare, and environmental factors; however, the contribution of regional geological characteristics remains poorly understood. This nationwide ecological study investigated whether the volcanic rock area ratio (VRAR) was associated with regional variation in acne medication utilisation across the 47 prefectures of Japan. Acne-specific prescription volumes for 2022 were obtained from the National Database of Health Insurance Claims and Specific Health Checkups of Japan and analysed using Spearman’s rank correlation, locally estimated scatterplot smoothing (LOESS), multivariable linear regression, influence and sensitivity analyses, and exploratory random forest modelling. A weak inverse correlation was observed between VRAR and acne-specific prescription volume per 100,000 population (ρ = −0.21, p = 0.160). LOESS suggested a possible non-linear pattern, with the lowest prescription volume occurring at intermediate VRAR values. However, quadratic regression did not provide statistical support for this pattern (p for VRAR2 = 0.494), and bootstrap analysis indicated substantial uncertainty in the estimated turning point. The direction of the correlation remained negative in all leave-one-prefecture-out analyses, and alternative assumptions regarding NDB small-count suppression produced materially unchanged results. In multivariable linear regression, VRAR remained negatively associated with prescription volume but did not reach statistical significance after covariate adjustment. These findings indicate an exploratory ecological pattern in the relationship between regional volcanic geological characteristics and acne medication utilisation but do not establish a statistically supported association, a stable non-linear relationship, or any specific environmental exposure or biological mechanism.
- 27 September 2026
- Published by MDPI AG in Environments
- Vol. 13 (10) , 537
Open AccessAssociation Between Volcanic Rock Area Ratio and Regional Variation in Acne Medication Utilisation in Japan: A Nationwide Ecological Study
Regional variation in healthcare utilisation is influenced by demographic, healthcare, and environmental factors; however, the contribution of regional geological characteristics remains poorly understood. This nationwide ecological study investigated whether the volcanic rock area ratio (VRAR) was associated with regional variation in acne medication utilisation across the 47 prefectures of Japan. Acne-specific prescription volumes for 2022 were obtained from the National Database of Health Insurance Claims and Specific Health Checkups of Japan and analysed using Spearman’s rank correlation, locally estimated scatterplot smoothing (LOESS), multivariable linear regression, influence and sensitivity analyses, and exploratory random forest modelling. A weak inverse correlation was observed between VRAR and acne-specific prescription volume per 100,000 population (ρ = −0.21, p = 0.160). LOESS suggested a possible non-linear pattern, with the lowest prescription volume occurring at intermediate VRAR values. However, quadratic regression did not provide statistical support for this pattern (p for VRAR2 = 0.494), and bootstrap analysis indicated substantial uncertainty in the estimated turning point. The direction of the correlation remained negative in all leave-one-prefecture-out analyses, and alternative assumptions regarding NDB small-count suppression produced materially unchanged results. In multivariable linear regression, VRAR remained negatively associated with prescription volume but did not reach statistical significance after covariate adjustment. These findings indicate an exploratory ecological pattern in the relationship between regional volcanic geological characteristics and acne medication utilisation but do not establish a statistically supported association, a stable non-linear relationship, or any specific environmental exposure or biological mechanism.
- 21 August 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 285
Risk factors for immune checkpoint inhibitor–related thyroid dysfunction: a retrospective cohort study
Purpose Immune checkpoint inhibitors (ICIs) are widely used to treat various malignancies; however, the high incidence of immune-related adverse events, including thyroid dysfunction, is a major clinical concern. Thyroid dysfunction occurs frequently, affects patient health and quality of life, and can be life-threatening when severe, necessitating prompt identification and management. Herein, we aimed to identify pretreatment risk factors associated with ICI-induced thyroid dysfunction. Methods Medical records of patients administered ICIs were retrospectively reviewed. Data on patient age, sex, and body weight; primary tumor type; ICI agent; programmed death-ligand 1 status; disease stage; line(s) of treatment; and laboratory parameters measured before treatment initiation were extracted. These characteristics were compared between patients who developed thyroid dysfunction and those who did not. Results An elevated pretreatment eosinophil count was significantly associated with thyroid dysfunction following ICI therapy. In the multivariable logistic regression analysis, eosinophil count remained significantly associated with thyroid dysfunction after adjustment for lactate dehydrogenase (LDH; adjusted odds ratio per 0.1 × 10³/µL increase, 2.18; 95% confidence interval [CI], 1.56–3.04; P < 0.001). Receiver operating characteristic analysis yielded an area under the curve of 0.812 (95% CI, 0.722–0.902). The optimal cutoff value was 0.2 × 10³/µL, with a sensitivity of 81.0% and a specificity of 68.2%. Conclusion An elevated pretreatment eosinophil count was associated with subsequent thyroid dysfunction following ICI therapy after adjustment for LDH. Further prospective studies incorporating thyroid autoantibody status are required to determine its clinical utility as a candidate marker.
- 21 August 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 285
Risk factors for immune checkpoint inhibitor–related thyroid dysfunction: a retrospective cohort study
Purpose Immune checkpoint inhibitors (ICIs) are widely used to treat various malignancies; however, the high incidence of immune-related adverse events, including thyroid dysfunction, is a major clinical concern. Thyroid dysfunction occurs frequently, affects patient health and quality of life, and can be life-threatening when severe, necessitating prompt identification and management. Herein, we aimed to identify pretreatment risk factors associated with ICI-induced thyroid dysfunction. Methods Medical records of patients administered ICIs were retrospectively reviewed. Data on patient age, sex, and body weight; primary tumor type; ICI agent; programmed death-ligand 1 status; disease stage; line(s) of treatment; and laboratory parameters measured before treatment initiation were extracted. These characteristics were compared between patients who developed thyroid dysfunction and those who did not. Results An elevated pretreatment eosinophil count was significantly associated with thyroid dysfunction following ICI therapy. In the multivariable logistic regression analysis, eosinophil count remained significantly associated with thyroid dysfunction after adjustment for lactate dehydrogenase (LDH; adjusted odds ratio per 0.1 × 10³/µL increase, 2.18; 95% confidence interval [CI], 1.56–3.04; P < 0.001). Receiver operating characteristic analysis yielded an area under the curve of 0.812 (95% CI, 0.722–0.902). The optimal cutoff value was 0.2 × 10³/µL, with a sensitivity of 81.0% and a specificity of 68.2%. Conclusion An elevated pretreatment eosinophil count was associated with subsequent thyroid dysfunction following ICI therapy after adjustment for LDH. Further prospective studies incorporating thyroid autoantibody status are required to determine its clinical utility as a candidate marker.
- 9 June 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 1-8
Risk factors for immune checkpoint inhibitor-related interstitial lung disease: a retrospective cohort study
Immune checkpoint inhibitors (ICIs) for cancer treatment show a high incidence of immune-related adverse events (irAEs), among which severe interstitial lung disease (ILD) can be fatal, requiring prompt identification and management. This study aimed to identify pre-treatment risk factors associated with ICI-induced ILD. Medical records of patients who received ICIs were retrospectively reviewed. Age, sex, body weight, primary tumor type, ICI agent, PD-L1 status, disease stage, line of treatment, and laboratory parameters measured before treatment initiation were collected. Smoking history and prior diagnoses of chronic obstructive pulmonary disease and ILD were recorded. Patients who developed ILD were compared with those who did not. Elevated pre-treatment C-reactive protein (CRP) levels (odds ratio [OR] = 1.877; 95% confidence interval [CI] = 1.238–2.845; p = 0.003) and increased monocyte counts (OR = 23.509; 95% CI = 1.375–4.020 × 102; p = 0.029) were potential risk factors for ILD development following ICI therapy. A multivariable logistic regression model incorporating pre-ICI CRP levels and monocyte counts was constructed to predict ILD risk. The receiver operating characteristic analysis of this model yielded an area under the curve of 0.808 with a sensitivity of 92.0% and a specificity of 63.9%. Elevated pre-treatment levels of CRP and monocytes were significantly associated with the subsequent ILD development in patients treated with ICIs. These findings underscore the importance of close monitoring for pulmonary toxicity in patients with elevated CRP and monocyte counts before initiating ICI therapy.
- 9 June 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 1-8
Risk factors for immune checkpoint inhibitor-related interstitial lung disease: a retrospective cohort study
Immune checkpoint inhibitors (ICIs) for cancer treatment show a high incidence of immune-related adverse events (irAEs), among which severe interstitial lung disease (ILD) can be fatal, requiring prompt identification and management. This study aimed to identify pre-treatment risk factors associated with ICI-induced ILD. Medical records of patients who received ICIs were retrospectively reviewed. Age, sex, body weight, primary tumor type, ICI agent, PD-L1 status, disease stage, line of treatment, and laboratory parameters measured before treatment initiation were collected. Smoking history and prior diagnoses of chronic obstructive pulmonary disease and ILD were recorded. Patients who developed ILD were compared with those who did not. Elevated pre-treatment C-reactive protein (CRP) levels (odds ratio [OR] = 1.877; 95% confidence interval [CI] = 1.238–2.845; p = 0.003) and increased monocyte counts (OR = 23.509; 95% CI = 1.375–4.020 × 102; p = 0.029) were potential risk factors for ILD development following ICI therapy. A multivariable logistic regression model incorporating pre-ICI CRP levels and monocyte counts was constructed to predict ILD risk. The receiver operating characteristic analysis of this model yielded an area under the curve of 0.808 with a sensitivity of 92.0% and a specificity of 63.9%. Elevated pre-treatment levels of CRP and monocytes were significantly associated with the subsequent ILD development in patients treated with ICIs. These findings underscore the importance of close monitoring for pulmonary toxicity in patients with elevated CRP and monocyte counts before initiating ICI therapy.
- Open Access
- 1 September 2025
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (5) , 552-556
Risk Factors for Infusion Reactions Associated With Rituximab Therapy
Background/Aim: Although rituximab is used to treat a range of diseases, the high frequency of rituximab-associated infusion reactions (IRs) poses a clinical challenge. This study aimed to identify pre-treatment risk factors associated with rituximab-induced IRs using retrospective patient data. Patients and Methods: We retrospectively analyzed the medical records of patients treated with rituximab. Data were compared between patients with and without IRs. Results: Among the variables assessed, an elevated C-reactive protein (CRP) level prior to rituximab administration was significantly associated with IR occurrence (odds ratio=2.591; 95% confidence interval=1.160-5.791; p=0.020). Conclusion: Elevated pre-medication levels of CRP are a significant risk factor associated with the use of rituximab, thereby highlighting the need for close monitoring of patients receiving rituximab who present with elevated CRP levels prior to the initiation of therapy.
- 1 September 2025
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (5) , 552-556
Open AccessRisk Factors for Infusion Reactions Associated With Rituximab Therapy
Background/Aim: Although rituximab is used to treat a range of diseases, the high frequency of rituximab-associated infusion reactions (IRs) poses a clinical challenge. This study aimed to identify pre-treatment risk factors associated with rituximab-induced IRs using retrospective patient data. Patients and Methods: We retrospectively analyzed the medical records of patients treated with rituximab. Data were compared between patients with and without IRs. Results: Among the variables assessed, an elevated C-reactive protein (CRP) level prior to rituximab administration was significantly associated with IR occurrence (odds ratio=2.591; 95% confidence interval=1.160-5.791; p=0.020). Conclusion: Elevated pre-medication levels of CRP are a significant risk factor associated with the use of rituximab, thereby highlighting the need for close monitoring of patients receiving rituximab who present with elevated CRP levels prior to the initiation of therapy.